Abzena plc

CAMBRIDGE, X0 · Founded 2014 · CIK 0001653673 · Biotech · Acquired

Integrated contract development and manufacturing organization (CDMO) and contract research organization (CRO) for antibody-based therapeutics, antibody-drug conjugates, antibody-oligonucleotide conju

abzena.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$4.3M
2 Form D · Dec 2015
130 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$700,000
Private capital raisedForm D · SEC$3,603,185
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2462Actym Therapeutics, Inc.—$25M
2463Verseon Corp—$25M
2464Pharmazz, Inc.—$25M
2465Abzena plc—$4.3M
2466CURADEL SURGICAL INNOVATIONS, INC.—$24M
2467Vaxart, Inc.—$23M
2468PULMOTECT, INC—$22M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 14 related persons
  • Matthew BakerExecutive Officer
  • Anthony BramptonDirector
  • Campbell BunceExecutive Officer
  • William BurtDirector · Executive Officer
  • Kenneth CunninghamDirector
  • Peter GrantDirector
  • Nareshkumar JainExecutive Officer
  • Anker LundemoseDirector
  • Jim MillsExecutive Officer
  • Gary PierceExecutive Officer
  • Leigh PierceExecutive Officer
  • Nigel PitchfordDirector
  • Julian SmithDirector · Executive Officer
  • Sally WatermanExecutive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.